Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REGN
DateTimeSourceHeadlineSymbolCompany
05/04/202206:05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
05/04/202206:04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
05/04/202206:04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
05/04/202206:03Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
04/04/202214:59PR Newswire (US)FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic EsophagitisNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/04/202207:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
02/04/202207:10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
02/04/202207:09Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
02/04/202207:09Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
01/04/202207:09Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
27/03/202200:59PR Newswire (US)Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo NodularisNASDAQ:REGNRegeneron Pharmaceuticals Inc
24/03/202207:03Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
24/03/202207:02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
19/03/202207:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
16/03/202212:16PR Newswire (US)Students Win $1.8 Million at Regeneron Science Talent Search 2022 for Exceptional Research on Neutron Star--Black Hole Systems, Narrowband Radar, and Ribosome Movement in Protein TranslationNASDAQ:REGNRegeneron Pharmaceuticals Inc
16/03/202207:01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
10/03/202207:18ValueWalkThe 3 Best Biotech Stocks To Buy In MarchNASDAQ:REGNRegeneron Pharmaceuticals Inc
04/03/202208:10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
02/03/202208:18Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
01/03/202208:02PR Newswire (US)Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing ProteinNASDAQ:REGNRegeneron Pharmaceuticals Inc
01/03/202208:01GlobeNewswire Inc.Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing ProteinNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/02/202204:04PR Newswire (US)Late-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic EsophagitisNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/02/202203:59PR Newswire (US)Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous UrticariaNASDAQ:REGNRegeneron Pharmaceuticals Inc
25/02/202208:13Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
25/02/202208:09Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
18/02/202216:59PR Newswire (US)Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 ProgramNASDAQ:REGNRegeneron Pharmaceuticals Inc
18/02/202208:05PR Newswire (US)Regeneron Announces Investor Conference PresentationsNASDAQ:REGNRegeneron Pharmaceuticals Inc
12/02/202200:51Dow Jones NewsRegeneron's Eye-Disorder Treatment Meets Primary Endpoint in Mid-Stage TrialNASDAQ:REGNRegeneron Pharmaceuticals Inc
11/02/202223:50PR Newswire (US)Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis MeetingNASDAQ:REGNRegeneron Pharmaceuticals Inc
11/02/202200:44Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:REGNRegeneron Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:REGN